Cellectar’s CLR 131 Receives Fourth RPDD
Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of osteosarcoma, the company announced recently. “Cellectar is pleased to have the opportunity to…
Tag Archives: Cellectar Biosciences
Cellectar’s CLR 131 Receives RPDD
Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of Ewing’s sarcoma, a rare pediatric cancer, by The U.S. Food and Drug Administration…
Cellectar Closes $16.56M Public Offering
Cellectar Biosciences today announced the effective prices of $4.00 per share of common stock of an underwritten public offering to raise approximately $16.56 million. According to a release, this includes the full…
Cellectar Reports Positive Data in Cancer Trial
Cellectar Biosciences announced today a patient, enrolled in the CLR 131 Phase 2 trial, showed a 94 percent reduction in tumor burden and complete resolution in four of five targeted…
Cellectar Granted RPDD by FDA
Cellectar Biosciences announced today that the U.S. Food and Drug Administration has granted rare pediatric disease designation (RPDD) to its phospholipid drug conjugate, CLR 131, for the treatment of neuroblastoma….
Cellectar Biosciences Nets Patent
The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent (No. P150207US03) that covers a method of use for CLR 131 in multiple myeloma, the company announced today….
Cellectar Receives Orphan Drug Designation
Cellectar Biosciences has been granted orphan drug designation for its therapeutic, CLR 131, by the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for the treatment of neuroblastoma,…
Cellectar Earns Allowance for Patent
The U.S. Patent and Trademark Office awarded Cellectar Biosciences a notice of allowance for a patent covering the use of CLR 131 in multiple myeloma (MM), the company announced today. “This patent…
Cellectar, Pierre Fabre Extend Relationship
Cellectar Biosciences has extended its collaboration with Pierre Fabre, a French pharmaceutical company, the company announced today. “The extension of our research agreement with Pierre Fabre allows us to further…
Cellectar, Onconova Therapeutics Collaborate
Cellectar Biosciences announced today it has entered into a strategic collaboration with Onconova Therapeutics, a biopharmaceutical company, to develop new phospholipid drug conjugates (PDC). According to a release, the Newtown,…
